In Science this week: series of reviews about gene modification, and more.
For the first time, researchers used mitochondrially targeted zinc-finger nucleases to induce specific elimination of mutant mtDNA across the heart.
Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.
The firm said it saw a robust contribution in the first half of the year from its Dharmacon business and noted that it increased its reach into the US market.
The international team then used the approach to show that appropriate guide RNA design can reduce off-target effects of editing in mouse livers.
The researchers said their findings could help classify BRCA1 variants, particularly one whose impact on cancer risk is currently not clear.
A new study shows that DNA targets bound by nucleosomes are cleaved less efficiently than targets lacking nucleosomes, which could inform target selection.
The court upheld a judgement of no interference-in-fact from the Patent Trial and Appeal Board, leaving the Broad in control of key CRISPR IP.
In Science this week: common metastatic driver genes, inhibitors of CRISPR, and more.
These Cas inhibitors — published in two studies — inhibit the activity of several Type V-A and Type I-C CRISPR systems, including several Cas12a orthologs.
The Associated Press reports that a state board in Texas has asked ANDE, a maker of rapid DNA machines, to halt its work there.
James Wyngaarden, the former director of the US National Institutes of Health, has died at 94, according to Duke University School of Medicine.
Researchers find that a 30-year-old skull comes from a narwhal-beluga hybrid, according to Science News.
In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.